INNOCARE (688428.SH): The data of ICP-488 treatment for psoriasis was released at the American Academy of Dermatology (AAD) annual meeting through a heavy-weight oral presentation.

INNOCARE (688428.SH) announcement: Recently, the company presented a groundbreaking oral report at the 2025 American Academy of Dermatology (AAD) annual meeting, titled "Efficacy and Safety of High Selective Oral TYK2 Inhibitor ICP-488 in the Treatment of Severe Plaque Psoriasis: A Randomized Double-Blind Placebo-Controlled Phase II Clinical Trial." The research results showed that ICP-488 at doses of 6mg once daily (QD) and 9mg once daily demonstrated significant efficacy in patients with psoriasis, as well as good safety and tolerability, providing a valuable treatment option for patients with moderate to severe psoriasis.